Sort   by:  
 Page size 
ProteomicsMetabolic crosstalk between skeletal muscle cells and liver through IRF4-FSTL1 in 2 nonalcoholic steatohepatitis
In this study Guo et al. revealed an endocrine pathway regulated by skeletal muscle IRF4 that manipulates liver pathology. Mice with skeletal muscle specific ablation of IRF4 show ameliorated liver steatosis, inflammation, and fibrosis, without changes in body weight on nonalcoholic steatohepatitis ...
ORGANISM(S): Mus musculus (Mouse) 
2023-09-13 | PXD045324 | Pride
Mouse serum lcms 
UnknownTau Contributes to Sevoflurane-induced Neurocognitive Impairment in Neonatal Mice.
Not available
S-EPMC7429299 | biostudies-literature
ProteomicsA chromatin re-localization screen for the identification of Poly-ADP-ribosylation (PARylation)-dependent DNA repair factors.
A chromatin re-localization screen for the identification of Poly-ADP-ribosylation (PARylation)-dependent DNA repair factors.
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD045229 | Pride
Chromatin relocalization parylation screen 
ProteomicsRNF114 Co-IP experiments to identify binding partners
To identify the substrates of RNF114 in the context of PARylation-mediated DDR, we performed an IP-MS (immunoprecipitation coupled with MS) experiment, using cells treated with either H2O2 or H2O2+Talazoparib. We identified a large number of PARP1 peptides from the RNF114 immunoprecipitants only in ...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD045231 | Pride
Rnf114 chromatin parp1 
ProteomicsUncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (i.e., PARP1 catalytic inhibition vs. PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is incompletely understood. Here we designed a series of small molecule PA...
ORGANISM(S): Rattus norvegicus (Rat) 
2019-08-01 | PXD014838 | Pride
Primary neonatal rat cardiomyocyte Irucaparib Irucaparib-tp5 Parp1 degradation 
ProteomicsUncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (i.e., PARP1 catalytic inhibition vs. PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is incompletely understood. Here we designed a series of small molecule PA...
ORGANISM(S): Homo sapiens (Human) 
2019-08-01 | PXD014840 | Pride
Rucaparib Parylated proteome Hela cell Irucaparib-tp3 Irucaparib 
ProteomicsUncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (i.e., PARP1 catalytic inhibition vs. PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is incompletely understood. Here we designed a series of small molecule PA...
ORGANISM(S): Homo sapiens (Human) 
2019-08-01 | PXD014836 | Pride
Hela cell Irucaparib-tp3 Parp1 degradation 
ProteomicsUncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (i.e., PARP1 catalytic inhibition vs. PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is incompletely understood. Here we designed a series of small molecule PA...
ORGANISM(S): Homo sapiens (Human) 
2019-08-01 | PXD014837 | Pride
Bt-549 cell Vrucaparib-tp4 Irucaparib-tp3 Parp1 degradation 
ProteomicsUncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (i.e., PARP1 catalytic inhibition vs. PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is incompletely understood. Here we designed a series of small molecule PA...
ORGANISM(S): Homo sapiens (Human) 
2019-08-01 | PXD014839 | Pride
Rucaparib Hela cell Irucaparib Parp trapping Chromatin 
ProteomicsInduced Degradation of Lineage-specific Oncoproteins Underlies the Selective PARP1 Inhibitor Toxicity in Small Cell Lung Cancer (batch2-6)
A subset of small cell lung cancer (SCLC) shows a clinical response to PARP inhibitors (PARPi) despite being proficient in homologous repair pathways. However, the underlying mechanism(s) of PARPi sensitivity is poorly understood. We performed quantitative proteomic analyses and identified proteomic...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD029968 | Pride
Quantitative proteomics Ascl1 Lineage-specific oncoproteins Synergistic effect Pips Parp1 inhibitor Predictive biomarkers A histone demethylase Brca1/2 Small cell lung cancer Homologous recombination 
Sort   by:  
 Page size